NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Novartis Pharmaceuticals
Conditions: Relapsing Multiple Sclerosis
Interventions: Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap), 13-valent pneumococcal conjugate vaccine (13-PCV), 23-valent pneumococcal polysaccharide vaccine (23-PPV), Seasonal Quadrivalent influenza vaccine
Countries: United States, Argentina, Australia, Austria, Belgium, Bulgaria, Canada, Croatia
The purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have participated in a Novartis ofatumumab clinical MS study. Vaccination sub-study The purpose of this research sub-study is to find out the effects of ofatumumab on the development of antibody responses to selected vaccines and keyhole limpet hemocyanin (KLH) neo-antigen in subjects with relapsing multiple sclerosis (RMS). COVID-19 sub-study: The purpose of this research sub-study is to explore the immune response following Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccination in a subset of subjects on long-term ofatumumab 20 mg sc. Note: Novartis is not supplying the SARS-CoV-2 vaccine.
Sex: ALL
Age: 18 Years to 100 Years
Healthy volunteers: No
Study type: INTERVENTIONAL
Inclusion Criteria: 1. Must have completed a selected Novartis MS study which dosed ofatumumab 20 mg sc every 4 weeks 2. Written informed consent Exclusion Criteria: * Emergence of any clinically significant condition/disease during the previous ofatumumab study in which study participation might result in safety risk for the subject * Subjects with active systemic bacterial, viral or fingal infections, or chronic infection (e.g. AIDS) * Subjects taking medications prohibited by the protocol * Pregnant or nursing (lactating) women Other protocol-defined inclusion/exclusion criteria may apply Vaccination sub-study: Inclusion criteria 1. Informed consent 2. Actively enrolled in the COMB157G2399 Study 3. 12 weeks of continuous treatment within the COMB157G2399 Study 4. prior vaccination history as per protocol-defined Exclusion criteria * known hypersensitivity or history of systemic allergic, neurologic or other reactions to vaccines * allergies to egg or shellfish * any safety findings including low IgG/IgM requiring ofatumumab interruption within 12 weeks prior to vaccination sub-study start * any major episode of infection requiring hospitalization or treatment with intravenous antibiotics within 2 weeks of the first vaccination sub-study visit Other protocol-defined inclusion/exclusion criteria may apply
- Birmingham, Alabama, United States
- Cullman, Alabama, United States
- Phoenix, Arizona, United States
- Fullerton, California, United States
- Sacramento, California, United States
- Aurora, Colorado, United States
- Basalt, Colorado, United States
- Boulder, Colorado, United States
- Colorado Springs, Colorado, United States
- Denver, Colorado, United States
- Fort Collins, Colorado, United States
- Newark, Delaware, United States
- Atlantis, Florida, United States
- Delray Beach, Florida, United States
- Hollywood, Florida, United States
- Homestead, Florida, United States
- Maitland, Florida, United States
- Miami, Florida, United States
- Naples, Florida, United States
- Oldsmar, Florida, United States
- Ormond Beach, Florida, United States
- Pensacola, Florida, United States
- Port Charlotte, Florida, United States
- Sarasota, Florida, United States
- Sarasota, Florida, United States
- Tallahassee, Florida, United States
- Tampa, Florida, United States
- Tampa, Florida, United States
- Tampa, Florida, United States
- West Palm Beach, Florida, United States
- + 265 more on CT.gov